Presented at Neuroscience 2021
ISU ABXIS (KOSDAQ: 086890), headquartered in Seongnam, a Korean biotechnology company developing new and novel bio-therapeutics to treat cancers and neurodegenerative diseases such as Alzheimer’s disease (AD), announced on November 19th that the research data on the discovery of first-in-class antibody therapeutics for AD was presented at Society for Neuroscience (SFN) 50th Annual Meeting: Neuroscience 2021 held virtually on November 8-11, 2021.
The presentation, on November 9th, featured the preclinical data of ISU203, a novel monoclonal antibody against acid sphingomyelinase (ASM) developed by ISU ABXIS in collaboration with the Kyungpook National University Industry-Academic Cooperation Foundation.
The activities of ASM are elevated in the blood of AD patients, which is found to be implicated in the AD pathology. Accordingly, targeting ASM would be a therapeutic target for the treatment of AD. In the AD animal model, the intraperitoneal administration of ISU203 diminished the ASM activity in the plasma, reduced the beta-amyloid peptides in the brain, and improved the cognitive dysfunctions. The expression of glial fibrillary acidic protein (GFAP), an astrocyte marker, was also decreased in the cortex and hippocampus of the AD mice.
The presented data implies that the anti-ASM monoclonal antibody would be one of therapeutic strategies for AD treatment.
Meanwhile, Neuroscience 2021 is one of the world's largest annual neuroscience conferences with 30,000 experts and scholars in the field of neuroscience, along with 500 global companies from 80 countries.
Poster Presentation Details
P236.07: Reduction of beta-amyloid pathology and improvement of cognitive functions in an Alzheimer’s disease mouse model by targeting acid sphingomyelinase in blood with a novel anti-ASM monoclonal antibody
Date and Time: November 9, 2021, 9:00 AM - 10:00 AM
Related Review Article